五年期多肽供应协议: Amylyx 和 Bachem 的经验教训

药丸 1: 在做出承诺之前量化您的需求不确定性

长期肽供应协议中最常见的错误是将数量承诺与需求预测绑定，而该需求预测尚未针对该计划的实际临床和监管不确定性进行压力测试.

Amylyx-Bachem 协议推迟了最低采购义务 2028 ——签约后至少两年. 这种差距不是慷慨; 人们认识到 avexitide 的商业量取决于 FDA 的批准时间, 标签范围, 以及在合同执行时仍未解决的付款人访问决策. 结构分离容量预留 (这可以尽早完成) 来自数量承诺 (仅当需求范围变得更容易处理时才开始).

在接受最低年度数量之前 (MAG) 条款, 在您的预测模型中运行三个场景:

• 基本情况: 在预期窗口内获得批准, 标签与目标指示相符

• 延误情况: 十二至十八个月的批准滞后, 不影响指示范围

• 不利的情况: 缩小标签批准范围, 限制市场准入, 或管道优先级降低

如果 MAQ 超过您的下行情况交易量 20-25% 以上, 您实际上是在为您可能永远不需要的容量等级购买保险，并在无法吸收保险时支付照付不议的罚款. 谈判降级条款，允许减少交易量下限，以响应记录在案的监管或商业触发因素. SEC 提交的 API 供应协议中的标准语言允许发起人援引不可抗力或重大不利变更条款, 但这些补救措施很难援引并且总是受到争议; 预先协商的降级机制在操作上更有用.

⚠️ 故障模式: 签署与基本案例发布假设相关的固定 MAQ, 然后，当延迟批准或限制标签将商业吸收量压缩到低于预期时，吸收无订单量 20-40% 的照付不议费用.

药丸 2: 了解您在预订经济学中实际支付的费用

多肽集团条款清单包括 $30 百万预付容量预留费——这个数字绝对值足够大，足以进行董事会层面的严格审查, 但这反映出大规模 GMP 肽生产能力的成本结构日益正常.

肽 CDMO 协议中的预留经济学现在通常包括两种不同的金融工具，而这两种工具经常被混为一谈:

1. 容量预留费 (病例报告表): 固定付款, 通常不可退款或只能部分抵扣未来的购买发票, 确保指定肽的指定制造槽位, 纯度规格, 批量大小, 并发布标准. 该费用补偿 CDMO 根据坚定承诺持有的能力，而不是趁机用其他客户的活动来填补它.

2. 维护费: 涵盖质量监督的经常性付款, 监管文件维护, 方法保留, 生产活动较少或无活跃期间的定期活动准备活动 - Amylyx-Bachem 披露的信息将其称为“维护费用和开支”。

这种区别对于财务建模很重要. CRF 是与期权价值相关的沉没资本成本; 维护费是经常性运营成本，即使在没有生产运行的情况下，这些成本也会持续存在. 两者都必须出现在协议期限内的净现成成本计算中.

签约前, 从协议草案中提取四个问题的答案:

1. CRF 是否完全可信, 部分可信, 或因取消而被没收?

2. 在什么条件下 CRF 可以转化为可执行的义务 (IE。, 期权什么时候变成负债)?

3. 什么会触发维护费发票, 以及其附带的审计权是什么?

4. 如果主站点无法满足预留的插槽, CDMO 是否有义务在备用合格设施中提供同等的位置 - 以及在什么时间内?

第三个问题在初稿协议中经常没有明确定义. 大规模运营的一级 CDMO 通常包含允许在定义的窗口内单方面重新安排保留时段的语言, 有时短至三十天, 赞助商没有金钱补救措施. 协商明确的补救措施——加速交付权, 规定期限内优先重新预订, 或费用抵免 - 在协议执行之前.

多肽合成 每 当前 CDMO 定价分析, Tier-1 CDMOs now routinely require 10–20% advance reservation deposits for research-scale agreements and 40–50% upfront non-refundable commitments for commercial-scale capacity. Understanding where your deal sits in that range — and why — is a foundational negotiation input.

药丸 3: 在锁定合作伙伴之前绘制技术转让准备情况

A supply agreement binds you commercially to a specific CDMO partner. Technical transfer complexity determines how easily you can exit that binding if circumstances change — and how much switching costs will constrain your negotiating leverage on renewals.

Peptide Contract Manufacturing Pricing Trends Q2 2026 places technology transfer costs for complex peptide APIs at $300,000–$800,000 or more, depending on process complexity, analytical method portfolio size, and GMP documentation burden. That range creates significant lock-in for programs with difficult sequences, multi-step modifications, or extensive stability-indicating method sets. The higher your transfer cost, the more leverage your CDMO has at renewal — and the more important it is to build transfer readiness into the original agreement.

Technical transfer readiness is best evaluated across four dimensions before signing:

An agreement that does not address method transfer protocol ownership, DMF filing rights, or post-agreement analytical record retention is one that hands the CDMO de facto veto power over any future transition. Negotiate:

• Sponsor access to batch records and analytical data within a defined period of request

• A right to conduct technical transfer to a qualified secondary or 合成肽 tertiary site during the agreement term (not only at termination)

• Specific timelines and cost-sharing provisions for any required re-validation at a new site

这 EMA 合成肽开发和生产指南 provides the regulatory baseline for what analytical controls must be in place for GMP-grade synthetic peptide APIs. Your transfer readiness assessment should verify that the CDMO’s current control strategy satisfies this standard — not merely that they assert it does.

对于小费: Request a “transfer readiness simulation” as part of final due diligence: ask the CDMO to provide the batch record index, method list, and DMF chapter inventory they would need to transfer to demonstrate readiness. Gaps in that inventory are negotiation leverage before signing — they become contractual disputes after.

药丸 4: 将应急采购纳入协议架构中, 不是事后的想法

The Amylyx-Bachem agreement is explicitly non-exclusive: Bachem is one of two simultaneously engaged CDMOs, with Polypeptide Group holding a parallel supply commitment. This structural choice reflects a clear risk management posture — single-source dependence for a commercial peptide API is no longer considered acceptable practice by biopharma legal and supply chain teams who have experienced the post-2020 supply disruption environment.

Dual-sourcing for peptide APIs is not simply about having a backup vendor on file. A backup vendor that has not completed analytical comparability, process qualification, or regulatory file alignment is operationally unavailable when you need it. The operational standard, validated by building a resilient peptide supply chain, is a staggered second-source protocol:

阶段 1 (Months 1–3): Desk audit and analytical method transfer to secondary vendor. CoA comparability study using split-lot samples. No active manufacturing commitment.

阶段 2 (Months 4–9): Pilot comparability batches at secondary site. Analytical equivalence assessment for identity (ESI-MS 或 MALDI-TOF), 纯度 (反相高效液相色谱法), and impurity profiles. Regulatory file alignment.

阶段 3 (进行中): Standing bridge allocation of 10–20% of routine purchase volume to secondary vendor. This maintains the secondary site’s production continuity and team familiarity with the process without incurring full commercial duplication costs.

The contingency sourcing provision in the primary supply agreement should explicitly address:

• The sponsor’s right to qualify and activate a secondary source during the agreement term, without triggering a breach-of-exclusivity claim (particularly if the primary agreement contains any preferred-supplier language)

• Defined escalation triggers that convert the secondary vendor from standby to primary allocation — delivery SLA failures, batch release failures above a defined frequency threshold, regulatory action, or material financial distress

• Supplier switching timeline commitments: what is the maximum number of days from trigger activation to first commercial batch delivery from the secondary source?

Per the dual-sourcing strategy guidance for biopharma, 一个 70/30 或者 60/40 commercial split across primary and secondary CDMOs is an operational benchmark that maintains secondary-source readiness without imposing equivalent cost to full parallel manufacturing.

⚠️ 故障模式: Qualifying a secondary CDMO on paper but not in practice — no pilot batches completed, no analytical comparability data on file, no regulatory filing amendments to add the alternate site. When the primary site has a capacity shortfall or quality excursion, the backup cannot legally supply commercial-grade material.

药丸 5: 以合同精度定义发布测试职责

Release testing responsibility is the most commonly under-specified element in peptide API supply agreements, and the most consequential when a batch fails or a specification dispute arises.

The Amylyx-Bachem agreement allocates testing and supply responsibilities to Bachem as the manufacturer, with Amylyx retaining product specification authority and final lot disposition rights as the sponsor/applicant. This is the standard architecture under ICH Q7 and standard industry quality agreements — but the details within that architecture matter enormously.

For a GMP synthetic peptide API, minimum release specifications require orthogonal analytical coverage per regulatory guidance. 根据 PolypPeptide’s CMC quality control white paper, lot release specifications must be sufficient to establish identity, 纯度, 力量, and where applicable, 安全 (内毒素, 不育) of the peptide API. A practical minimum release panel includes:

Beyond the panel itself, the quality agreement attached to the supply agreement must clearly assign responsibility for:

• Testing authority: who performs each test, and at which site (CDMO QC, sponsor QC, or independent third-party laboratory)?

• OOS investigation ownership: when a result falls outside specification, who initiates the investigation, what is the timeline, and what authority does the CDMO have to release a lot pending investigation resolution?

• Lot disposition authority: the CDMO typically performs provisional internal QC disposition; the sponsor retains final release authority for GMP lots intended for clinical or commercial use

• CoA format and data retention: the CoA must include batch number, all test results with raw data references (色谱图, 光谱), analyst ID, 和发布日期. Data retention obligations and sponsor access rights should be defined contractually, not left to the CDMO’s internal SOPs

This distribution of testing and disposition authority is the contractual backbone of your lot-level risk management. When a batch fails, ambiguity about who owns the investigation or the release decision translates directly to timeline risk and regulatory exposure.

应用框架: 预签名清单

The five pillars above convert to a structured pre-signature review that can be completed across a standard legal and technical due diligence cycle. For each pillar, the minimum acceptance condition is:

Any cell left blank or answered with “to be defined” before signing is a gap that will need to be resolved — under worse conditions — after execution.

与您的 CDMO 合作伙伴就协议条款进行合作

The framework above is an evaluation and negotiation tool, not a prescriptive contract template. Real supply agreement negotiations involve counterpart constraints, market capacity realities, and relationship context that generic checklists cannot capture. The most productive outcome of applying this framework is a structured conversation with your CDMO counterpart about which provisions are standard, which are negotiable, and which require creative structural solutions.

For biopharma development teams building peptide programs from the milligram-to-kilogram scale, having a CDMO partner with explicit expertise in technical transfer, 分析方法开发, and quality agreement architecture reduces the friction in each of these five areas. 商船三井的变化 supports peptide synthesis programs across the full development continuum — from complex custom sequences requiring 300+ functional group modifications to GMP-compatible production in Class 100 cleanroom environments with full HPLC, 多发性硬化症, and endotoxin QC — and can provide a technical feasibility assessment to help teams understand their specific agreement risk profile before negotiations begin.

The Amylyx-Bachem agreement, read at the level of its contractual mechanics rather than its headline announcement, is a useful reference point. Every team entering a multi-year peptide supply commitment should be able to account for each of the five pillars described above — not because the deal terms are identical to Amylyx’s, but because the categories of risk are.

Reviewed by the MOL Changes Peptide Science Team. MOL Changes is a commercial-stage peptide synthesis and CDMO services provider; the framework in this article reflects industry-standard practice and publicly available regulatory guidance, not proprietary claims.